Bulletin of Experimental Biology and Medicine

, Volume 151, Issue 3, pp 353–355 | Cite as

Role Sympathetic Autonomic Nervous System in the Regulation of Immune Response during Myasthenia

Immunology and Microbiology
  • 56 Downloads

In 12 patients with myasthenia, the content of β2-adrenoreceptors on the cell surface and activity of intracellular lymphocytic enzymes were determined by EIA and biochemical methods, respectively. In comparison with the normal, these patients demonstrated pronounced elevation in the content of β2-adrenoreceptors and significant changes in activity of lymphocytic enzymes. In 10 of 12 patients, administration of the agonists to β2-adrenoreceptors resulted in health improvement accompanied by normalization of EMG and immunobiochemical indices. Our findings suggest that intra- and intercellular signaling pathways and their modification can serve as potential targets for the therapy.

Key Words

myasthenia β2-adrenoreceptor enzyme immune assay salbutamol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. M. Vein, T. G. Voznesenskaya, and V. L. Golubev, Diseases of Autonomic Nervous System, Ed. A. M. Vein [in Russian], Moscow (1991).Google Scholar
  2. 2.
    G. N. Kryzhanovskii, S. V. Magaeva, S. V. Makarov, and R. I. Sepishvili, Textbook on Neural Immunopathology [in Russian], Moscow, (2003).Google Scholar
  3. 3.
    I. J. Elenkov, D. A. Papanicolaou, R. L. Wilder, and G. P. Chrousos, Proc. Assoc. Am. Physicians, 108, No. 5, 374–381 (1996).PubMedGoogle Scholar
  4. 4.
    R. Elies, I. Ferrari, G. Wallukat, D. Lebesgue, et al., J. Immunol., 157, No. 9, 4203–4211 (1996).PubMedGoogle Scholar
  5. 5.
    K. Kawashima and T. Fujii, Life Sci., 74, No. 6, 675–696 (2003).PubMedCrossRefGoogle Scholar
  6. 6.
    V. M. Sanders, R. A. Baker, D. S. Ramer-Quinn, et al., J. Immunol., 158, No. 9, 4200–4210 (1997).PubMedGoogle Scholar
  7. 7.
    K. Wiegmann, S. Muthyala, D. H. Kim, et al., J. Neuroimmunol., 56, No. 2, 201–206 (1995).PubMedCrossRefGoogle Scholar
  8. 8.
    B. Xu, Q. Yi, R. Pirskanen, et al., J. Autoimmun., 10, No. 4, 401–406 (1997).PubMedCrossRefGoogle Scholar
  9. 9.
    B. Y. Xu, D. Huang, R. Pirskanen, and A. K. Lefvert, Clin. Exp. Immunol., 119, No. 1, 156–160 (2000).PubMedCrossRefGoogle Scholar
  10. 10.
    J. Z. Xu, Chung Hua Shen Ching Ching Shen Кo Tsa Chih., 26, No. 6, 361–385 (1992).Google Scholar
  11. 11.
    I. Yamamoto and K. Iwata, J. Immunoassay, 3, No. 2, 155–171 (1982).PubMedCrossRefGoogle Scholar
  12. 12.
    Y. Zoukos, T. N. Thomaides, D. Kidd, et al., J. Neurol. Neurosurg. Psychiatry, 74, No. 2, 197–202 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2011

Authors and Affiliations

  • V. B. Lantsova
    • 1
    • 2
  • E. K. Sepp
    • 1
    • 2
  • A. S. Kozlovsky
    • 1
    • 2
  1. 1.State Research Institute of General Pathology and Pathological Physiology, Russian Academy of Medical SciencesMoscowRussia
  2. 2.Children’s Clinical Hospital, Ministry of Health Care and Social Development of the Russian FederationMoscowRussia

Personalised recommendations